Related Experiment Video
Updated: Jul 28, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Angioarrestin mRNA expression in early-stage lung cancers
H Sasaki1, S Moriyama, A Sekimura
1Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. hisasaki@med.nagoya-cu.ac.jp
Summary
Decreased angioarrestin gene expression is observed in lung cancer, particularly in early stages and lymph node-negative tumors. This suggests angioarrestin may inhibit tumor progression and play a role in oncogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Gene Expression Analysis
Background:
- Angioarrestin is a novel angiogenesis inhibitor.
- Angiogenesis is crucial for tumor development.
- Angioarrestin expression is reportedly reduced in lung cancer.
Purpose of the Study:
- To investigate the correlation between angioarrestin expression and clinicopathological features in lung cancer patients.
- To understand the role of angioarrestin in lung cancer progression.
Main Methods:
- Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to measure angioarrestin mRNA levels.
- 93 lung carcinoma and adjacent normal lung tissue samples were analyzed.
- Expression levels were quantified relative to GAPDH.
Main Results:
- Angioarrestin/GAPDH mRNA expression was significantly lower in lung tumors compared to normal lung tissue (p<0.0001).
- Decreased angioarrestin expression was associated with early-stage (Stage I) lung cancer (p=0.0316).
- Reduced angioarrestin levels were observed in lymph node-negative (N0) tumors compared to N2 tumors (p=0.0362).
Conclusions:
- Reduced angioarrestin mRNA expression appears to be an early event in lung cancer progression.
- Loss of angioarrestin's anti-angiogenic function may contribute to lung cancer development.
- Angioarrestin may serve as a potential biomarker for early-stage lung cancer.
